1
|
Dehshiri M, Mansouri M, Jarahzadeh MH, Hatamizadeh N. Determinants of Non-Acceptance of the COVID-19 Vaccine During Pregnancy in Pregnant and Postpartum Women: A Descriptive Cross-Sectional Study. J Family Reprod Health 2024; 18:67-74. [PMID: 38863837 PMCID: PMC11162888 DOI: 10.18502/jfrh.v18i1.15441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2024] Open
Abstract
Objective The rate of COVID-19 vaccination hesitation among Iranian pregnant women is around 50%. The objective of the present study was to determine the reasons for the refusal of COVID-19 vaccination among pregnant and postpartum women. Materials and methods This descriptive cross-sectional study was performed on 304 pregnant and postpartum women in the comprehensive health centers of Yazd, Iran, between October 2022 and April 2023. Researchers collected the data of unvaccinated women through phone calls using a validated questionnaire. Data was collected using a questionnaire consisting of baseline characteristics and reasons for refusing vaccination. Descriptive statistics were used to analyze the data using SPSS version 22. Results The mean age of the pregnant and postpartum women participating in this study was 28.31 ± 6.47 years. The most common reasons for refusing the COVID-19 vaccine included fear of harming the fetus (32.2%), fear of side effects in the mother (25.7%), disbelief in COVID-19 disease and vaccine (13.8%), lack of information about the vaccine (12.8%), and negative opinions of the media and society (12.8%). Less common reasons included husband's disagreement (8.2%), history of COVID-19 infection (6.9%), gynecologists' disagreement (6.3%), history of infertility (5.9%), and underlying disease (3.3%). Astonishingly, among participants who did not inject a booster dose of the vaccine, 76% reported they didn't receive any training and recommendation on booster dose injection from health providers. Conclusion Findings highlight that the most common reasons for refusing the COVID-19 vaccine were fear of harming the fetus and fear of side effects in the mother.
Collapse
Affiliation(s)
- Maryam Dehshiri
- Department of Midwifery, Islamic Azad University, Meybod, Iran
| | | | | | - Nooshin Hatamizadeh
- Department of Obstetrics and Gynecology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| |
Collapse
|
2
|
Barbhaiya M, Schneider B, Levine JM, Bruce O, Do H, Siegel CH, Bykerk VP, Feldman CH, Jannat-Khah D, Mandl LA. Factors Associated With COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City. J Clin Rheumatol 2024; 30:e1-e8. [PMID: 37946323 DOI: 10.1097/rhu.0000000000002041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2023]
Abstract
OBJECTIVE The aim of this study was to measure COVID-19 vaccine hesitancy among rheumatology outpatients from an early COVID-19 "hotspot" during the initial period of vaccine availability. METHODS In March 2021, a Web-based survey was sent to 7505 adults seen at a Rheumatology Division in New York City. We evaluated characteristics associated with 3 categories of COVID-19 vaccination status: declined, undecided, and willing/already received. We used multinomial logistic regression models to calculate relative risk ratios assessing predictors of vaccination status. RESULTS Among 2384 (32%) respondents (80% female, 87% White, 59% with systemic rheumatic disease), 2240 (94.0%) were willing/already received COVID-19 vaccination, 88 (3.7%) were undecided, and 56 (2.3%) declined. Compared with those willing/already vaccinated, those declining or undecided were younger, more likely identified as Black or Hispanic/Latinx, and had lower household income and educational attainment. Immunosuppressive medication use did not differ among groups. After multivariable adjustment, every 1-year increase in age was associated with a 0.96 lower relative risk of declining or being undecided versus willing/already vaccinated. Respondents identifying as Black versus White had a higher relative risk ratio of being undecided (4.29 [95% confidence interval, 1.96-9.36]), as did those identifying as Hispanic/Latinx versus non-Hispanic/non-Latinx (2.81 [95% confidence interval, 1.29-6.09]). Those declining vaccination were least likely to believe in general vaccine importance or the safety and efficacy of the COVID-19 vaccine. CONCLUSIONS Among rheumatology patients in New York City with and without systemic rheumatic disease, COVID-19 vaccine uptake was high after its initial availability. Sociodemographic but not medication-related factors were associated with vaccine hesitancy; these findings can inform future rheumatology vaccination programs.
Collapse
Affiliation(s)
| | | | | | - Omar Bruce
- Hospital for Special Surgery, New York, NY
| | - Huong Do
- Hospital for Special Surgery, New York, NY
| | | | | | - Candace H Feldman
- Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, MA
| | | | | |
Collapse
|
3
|
Santana F, Rezende R, Paschoal N, Rocha L, Lopes J, Perez M, Bunjes B, Dório M, Furquim M, Cobra J, Sales L, Figueiredo C. COVID-19 vaccine confidence in the post-vaccination era: Perceptions among adults with immune-mediated inflammatory diseases. PUBLIC HEALTH IN PRACTICE 2023; 6:100419. [PMID: 37608848 PMCID: PMC10440544 DOI: 10.1016/j.puhip.2023.100419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Accepted: 08/04/2023] [Indexed: 08/24/2023] Open
Abstract
Objective Assess the perceived protection afforded by a range of COVID-19 vaccines in immune-mediated inflammatory diseases patients previously vaccinated against SARS-CoV-2. Study design Survey. Methods On-line cross-sectional survey aimed at evaluating the perceived protection (and its determinants) afforded by a range of COVID-19 vaccines among immune-mediated inflammatory diseases previously vaccinated for COVID-19. Results Out of 493 eligible respondents who lived in Brazil, 397 (80.5%) were confident that their primary vaccination series would protect them against severe COVID-19. In multivariate analysis, only overlapping immune-mediated inflammatory diseases remained (negatively) associated with the perception of protection. Conclusions No influence was found between COVID-19 vaccine types and the perception of protection after initial vaccinations.
Collapse
Affiliation(s)
- F.M. Santana
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
| | - R.P.V. Rezende
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
- Universidade Federal Fluminense, Divisão de Reumatologia, Departamento de Medicina Clínica (MMC), Niterói, Rio de Janeiro, Brazil
| | - N.O.S. Paschoal
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
| | - L.F. Rocha
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
| | - J.B. Lopes
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
| | - M.O. Perez
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
| | - B.G. Bunjes
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
| | - M. Dório
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
- Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - M.A.D. Furquim
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
- Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - J.F. Cobra
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
| | - L.P. Sales
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
- Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - C.P. Figueiredo
- Instituto de Reumatologia de São Paulo, São Paulo, São Paulo, Brazil
- Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| |
Collapse
|
4
|
Gonçalves BA, Matos CCDSA, Ferreira JVDS, Itagyba RF, Moço VR, Couto MT. COVID-19 vaccine hesitancy in Latin America and Africa: a scoping review. CAD SAUDE PUBLICA 2023; 39:e00041423. [PMID: 37556613 PMCID: PMC10494688 DOI: 10.1590/0102-311xpt041423] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 05/16/2023] [Accepted: 05/25/2023] [Indexed: 08/11/2023] Open
Abstract
Vaccination has played an important role in the containment of COVID-19 pandemic advances. However, SARS-CoV-2 vaccine hesitancy has caused a global concern. This scoping review aims to map the scientific literature on COVID-19 vaccine hesitancy in Latin America and Africa from a Global Health perspective, observing the particularities of the Global South and using parameters validated by the World Health Organization (WHO). The review reporting observes the recommendations of the PRISMA for Scoping Reviews (PRISMA-ScR) model. Search was conducted in PubMed, Scopus, Web of Science, and Virtual Health Library (VHL) databases, selecting studies published from January 1, 2020 to January 22, 2022. Selected studies indicate that COVID-19 vaccine hesitancy involves factors such as political scenario, spread of misinformation, regional differences in each territory regarding Internet access, lack of access to information, history of vaccination resistance, lack of information about the disease and the vaccine, concern about adverse events, and vaccine efficacy and safety. Regarding the use of conceptual and methodology references from the WHO for vaccine hesitancy, few studies (6/94) use research instruments based on these references. Then, the replication in Global South of conceptual and methodological parameters developed by experts from the Global North contexts has been criticized from the perspective of Global Health because of it may not consider political and sociocultural particularities, the different nuances of vaccine hesitancy, and issues of access to vaccines.
Collapse
|
5
|
Mavragani A, Oh B, Yoon NH, Kim S, Jung YI. The Evaluation of Web-Based Communication Interventions to Support Decisions About COVID-19 Vaccination Among Patients With Underlying Medical Conditions: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2023; 12:e42837. [PMID: 36599054 PMCID: PMC9855572 DOI: 10.2196/42837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 12/30/2022] [Accepted: 01/03/2023] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND The timeliness of raising vaccine acceptance and uptake among the public is essential to overcoming COVID-19; however, the decision-making process among patients with underlying medical conditions is complex, leading individuals to vaccine hesitancy because of their health status. Although vaccine implementation is more effective when deployed as soon as possible, vaccine hesitancy is a significant threat to the success of vaccination programs. OBJECTIVE This study aims to evaluate the effectiveness of a communication tool for patients with underlying medical conditions who should decide whether to receive a COVID-19 vaccine. METHODS This 3-arm prospective randomized controlled trial will test the effect of the developed communication intervention, which is fully automated, patient decision aid (SMART-DA), and user-centered information (SMART-DA-α). The web-based intervention was developed to help decision-making regarding COVID-19 vaccination among patients with underlying medical conditions. Over 450 patients will be enrolled on the web from a closed panel access website and randomly assigned to 1 of 3 equal groups stratified by their underlying disease, sex, age, and willingness to receive a COVID-19 vaccine. SMART-DA-α provides additional information targeted at helping patients' decision-making regarding COVID-19 vaccination. Implementation outcomes are COVID-19 vaccination intention, vaccine knowledge, decisional conflict, stress related to decision-making, and attitudes toward vaccination, and was self-assessed through questionnaires. RESULTS This study was funded in 2020 and approved by the Clinical Research Information Service, Republic of Korea. Data were collected from December 2021 to January 2022. This paper was initially submitted before data analysis. The results are expected to be published in the winter of 2023. CONCLUSIONS We believe that the outcomes of this study will provide valuable new insights into the potential of decision aids for supporting informed decision-making regarding COVID-19 vaccination and discovering the barriers to making informed decisions regarding COVID-19 vaccination, especially among patients with underlying medical conditions. This study will provide knowledge about the common needs, fears, and perceptions concerning vaccines among patients, which can help tailor information for individuals and develop policies to support them. TRIAL REGISTRATION Korea Clinical Information Service KCT0006945; https://cris.nih.go.kr/cris/search/detailSearch.do/20965. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/42837.
Collapse
Affiliation(s)
| | - Bumjo Oh
- Department of Family Medcine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea
| | - Nan-He Yoon
- Division of Social Welfare and Health Administration, Wonkwang University, Ik-san, Republic of Korea
| | - Shinkyeong Kim
- Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea
| | - Young-Il Jung
- Department of Environmental Health, Korea National Open University, Seoul, Republic of Korea
| |
Collapse
|
6
|
Bussink-Voorend D, Hautvast JLA, Vandeberg L, Visser O, Hulscher MEJL. A systematic literature review to clarify the concept of vaccine hesitancy. Nat Hum Behav 2022; 6:1634-1648. [PMID: 35995837 DOI: 10.1038/s41562-022-01431-6] [Citation(s) in RCA: 56] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Accepted: 07/13/2022] [Indexed: 11/25/2022]
Abstract
Vaccine hesitancy (VH) is considered a top-10 global health threat. The concept of VH has been described and applied inconsistently. This systematic review aims to clarify VH by analysing how it is operationalized. We searched PubMed, Embase and PsycINFO databases on 14 January 2022. We selected 422 studies containing operationalizations of VH for inclusion. One limitation is that studies of lower quality were not excluded. Our qualitative analysis reveals that VH is conceptualized as involving (1) cognitions or affect, (2) behaviour and (3) decision making. A wide variety of methods have been used to measure VH. Our findings indicate the varied and confusing use of the term VH, leading to an impracticable concept. We propose that VH should be defined as a state of indecisiveness regarding a vaccination decision.
Collapse
Affiliation(s)
- Daphne Bussink-Voorend
- Radboud University Medical Center, Radboud Institute for Health Sciences, Primary and Community Care, Nijmegen, the Netherlands.
| | - Jeannine L A Hautvast
- Radboud University Medical Center, Radboud Institute for Health Sciences, Primary and Community Care, Nijmegen, the Netherlands
| | - Lisa Vandeberg
- Behavioural Science Institute, Radboud University, Nijmegen, the Netherlands
| | - Olga Visser
- Radboud University Medical Center, Radboud Institute for Health Sciences, Primary and Community Care, Nijmegen, the Netherlands
| | - Marlies E J L Hulscher
- Radboud University Medical Center, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, the Netherlands
| |
Collapse
|
7
|
Guaracha-Basañez GA, Contreras-Yáñez I, Álvarez-Hernández E, Reyes-Cordero G, Flores-Alvarado DE, González-Chávez SA, Galarza-Delgado DÁ, Martínez-Leyva PR, Moctezuma-Ríos JF, García-García C, Medrano-Ramírez G, Gastelum-Strozzi A, Pacheco-Tena C, Peláez-Ballestas I, Pascual-Ramos V. Factors associated to COVID-19 vaccine acceptance in Mexican patients with rheumatic diseases: A cross-sectional and multicenter study. Hum Vaccin Immunother 2022; 18:2049131. [PMID: 35389817 PMCID: PMC9196644 DOI: 10.1080/21645515.2022.2049131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
COVID-19 vaccination is recommended in patients with rheumatic diseases (RDs) to prevent hospitalized COVID-19 and worse outcomes. However, patients’ willingness to receive a SARS-CoV-2 vaccine and the associated factors vary across populations, vaccines, and time. The objective was to identify factors associated with COVID-19 vaccine acceptance (VA) in Mexican outpatients with RDs. This multicenter study was performed between March 1 and September 30, 2021, and four national centers contributed with patients. Participants filled out a questionnaire, which included 32 items related to patients’ perception of the patient-doctor relationship, the COVID-19 vaccine component, the pandemic severity, the RD-related disability, comorbid conditions control, immunosuppressive treatment impact on the immune system, and moral/civil position of COVID-19 vaccine. Sociodemographic, disease-related, and treatment-related variables and previous influenza record vaccination were also obtained. Multiple logistic regression analyses identified factors associated with VA, which was defined based on a questionnaire validated in our population. There were 1439 patients whose data were analyzed, and the most frequent diagnoses were Rheumatoid Arthritis in 577 patients (40.1%) and Systemic Lupus Erythematosus in 427 (29.7%). Patients were primarily middle-aged women (1235 [85.8%]), with (mean±SD) 12.1 (±4.4) years of formal education. Years of education, corticosteroid use, patient perceptions about the vaccine and the pandemic severity, patient civil/moral position regarding COVID-19 vaccine, and previous influenza vaccination were associated with VA. In Mexican patients with RDs, COVID-19 VA is associated with individual social-demographic and disease-related factors, patient´s perceptions, and previous record vaccination. This information is crucial for tailoring effective vaccine messaging in Mexican patients with RDs.
Collapse
Affiliation(s)
- Guillermo Arturo Guaracha-Basañez
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico
| | - Irazú Contreras-Yáñez
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico
| | | | | | - Diana Elsa Flores-Alvarado
- Rheumatology Department, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico
| | | | - Dionicio Ángel Galarza-Delgado
- Rheumatology Department, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico
| | - Perla Rocío Martínez-Leyva
- Rheumatology Department, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico
| | | | - Conrado García-García
- Department of Rheumatology, Hospital General de México "Dr. Eduardo Liceaga", México City, México
| | - Gabriel Medrano-Ramírez
- Department of Rheumatology, Hospital General de México "Dr. Eduardo Liceaga", México City, México
| | | | - César Pacheco-Tena
- Facultad de Medicina y Universidad Autónoma de Chihuahua, Chihuahua, Mexico
| | - Ingris Peláez-Ballestas
- Department of Rheumatology, Hospital General de México "Dr. Eduardo Liceaga", México City, México
| | - Virginia Pascual-Ramos
- Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico
| |
Collapse
|
8
|
Celis Camargo AM, Jay Romero JA, Pizarro Nieto GA, Reyes Lobo A, Comincini Cantillo E. COVID-19 y rinosinusitis invasiva aguda secundaria a mucormicosis: a propósito de 2 casos en Colombia. REPERTORIO DE MEDICINA Y CIRUGÍA 2022. [DOI: 10.31260/repertmedcir.01217372.1359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Introducción: la mucormicosis es una infección micótica poco frecuente, también conocida como zigomicosis o phycomycosis, de baja prevalencia, pero con alta mortalidad, por lo regular ocasionada por estados de inmunosupresión como los que ocurren después de infecciones por COVID-19, teniendo esta asociación patológica una alta tasa de mortalidad y secuelas en la salud de los que la padecen. Presentación de los casos: son dos casos de mucormicosis rinocerebral asociados con COVID-19 y se describen el manejo y los desenlaces.
Collapse
|
9
|
Kocyigit BF, Akyol A. The relationship between COVID-19 and fibromyalgia syndrome: prevalence, pandemic effects, symptom mechanisms, and COVID-19 vaccines. Clin Rheumatol 2022; 41:3245-3252. [PMID: 35804273 DOI: 10.1007/s10067-022-06279-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 06/17/2022] [Accepted: 07/01/2022] [Indexed: 11/29/2022]
Abstract
On March 11, 2020, the World Health Organization, realizing the level of spread worldwide and the severity of the condition, accepted coronavirus disease 19 (COVID-19) as a pandemic. Subsequently, quarantine conditions were implemented around the world, and these triggered particular results. Like all other individuals, fibromyalgia syndrome (FMS) patients were affected by these conditions. The stress load in pandemic conditions, difficulties in accessing healthcare services, changes in exercise compliance, variations in physiotherapy programs, and remote work conditions all had an impact on FMS patients. Although general expectations were negative, some FMS patients were able to manage the pandemic conditions and even turn them in their favor. This is thought to be due to this patient group having established strategies to cope with stress in the pre-pandemic period, and they had sufficient ability to adapt to changing situations. FMS-related symptoms occur in a subset of individuals following COVID-19. One of the factors is the increased psychological burden after COVID-19. There is evidence that neuroinflammatory pathways affect neuroplasticity in the central nervous system and trigger the onset of FMS-related symptoms. Among the probable mechanisms are alterations in inflammatory and anti-inflammatory pathways. Changes in the autonomic nervous system with the effect of SARS-CoV-2 may induce the emergence of FMS-related symptoms. FMS and COVID-19 can coexist, and FMS may create a tendency to vaccine hesitancy. Future studies should focus on elucidating FMS-related symptoms occurring post-COVID-19. There is a need to determine distinctions between the FMS clinical status that emerged following COVID-19 and the regular patient group in terms of diagnosis, treatment, and follow-up.
Collapse
Affiliation(s)
- Burhan Fatih Kocyigit
- Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.
| | - Ahmet Akyol
- Physiotherapy and Rehabilitation Application and Research Center, Hasan Kalyoncu University, Gaziantep, Turkey
| |
Collapse
|
10
|
Mehta P, Gasparyan AY, Zimba O, Kitas GD. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. Clin Rheumatol 2022; 41:2893-2910. [PMID: 35639259 PMCID: PMC9152659 DOI: 10.1007/s10067-022-06227-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 05/19/2022] [Accepted: 05/23/2022] [Indexed: 02/07/2023]
Abstract
Patients with systemic lupus erythematosus (SLE) form a vulnerable group in terms of the impact of the COVID-19 pandemic on disease management. We conducted this overview by searches through Medline/PubMed, Scopus, and the Directory of Open Access Journals (DOAJ). The prevalence and severity of COVID-19, efficacy of COVID-19 vaccination, impact on the management of SLE, and the attitudes of SLE patients to COVID-19 and vaccination were explored. After screening and due exclusions, 198 studies were included for the final review. Patients with SLE have a greater risk of acquiring COVID-19 (0.6-22%) and related hospitalization (30%), severe disease (13.5%), and death (6.5%) than the general population. Older age, male gender, comorbidities, moderate or high disease activity, and glucocorticoid, rituximab, and cyclophosphamide use are associated with unfavorable outcomes, whereas methotrexate and belimumab use showed no association with outcomes. COVID-19 vaccines are safe in SLE with minimal risk of severe flares (< 2%). Vaccine efficacy is negatively associated with glucocorticoids. The overall attitude of patients towards vaccination is positive (54-90%). The pandemic has negatively affected access to medical care, hospitalizations, procurement of drugs, employment, and the mental health of patients which need to be addressed as part of holistic care in SLE. Key Points • Lupus patients are at a greater risk of acquiring COVID-19, related hospitalization, severe disease, and death than the general population. • COVID-19 vaccines are relatively safe for lupus patients with minimal risk of severe flares. • Lupus patients' attitude towards COVID-19 vaccination is predominantly positive.
Collapse
Affiliation(s)
- Pankti Mehta
- Department of Clinical Immunology and Rheumatology, King George's Medical University, Lucknow, India
| | - Armen Yuri Gasparyan
- Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Pensnett Road, Dudley, DY1 2HQ, UK.
| | - Olena Zimba
- Department of Internal Medicine N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
| | - George D Kitas
- Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Pensnett Road, Dudley, DY1 2HQ, UK
- Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK
| |
Collapse
|
11
|
Putman M, Kennedy K, Sirotich E, Liew JW, Sattui SE, Moni TT, Akpabio AA, Alpizar-Rodriguez D, Angevare S, Beesley RP, Berenbaum F, Bulina I, Chock YPE, Conway R, Duarte-García A, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard R, Hoyer BF, Hsieh E, El Kibbi L, Kilian A, Kim AHJ, Liew DFL, Lo C, Mateus EF, Miller B, Mingolla S, Nudel M, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Zamora-Tehozol EA, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché MJ, Levine M, Foster G, Thabane L, Hausmann JS, Sparks JA, Simard JF. COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. THE LANCET. RHEUMATOLOGY 2022; 4:e237-e240. [PMID: 35156060 PMCID: PMC8824526 DOI: 10.1016/s2665-9913(22)00001-7] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | - Kevin Kennedy
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Emily Sirotich
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- Canadian Arthritis Patient Alliance, Toronto, ON, Canada
| | - Jean W Liew
- Section of Rheumatology, Boston University School of Medicine, Boston, MA, USA
| | - Sebastian E Sattui
- Division of Rheumatology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburg, PA, USA
| | - Tarin T Moni
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Akpabio A Akpabio
- Department of Rheumatology, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
| | | | - Saskya Angevare
- Stichting KAISZ, Amsterdam, The Netherlands
- ENCA, Paris, France
- Autoinflammatory Alliance, Amsterdam, The Netherlands
| | | | - Francis Berenbaum
- Sorbonne University, INSERM, AP-HP Saint-Antoine hospital, Paris, France
| | - Inita Bulina
- Center of Rheumatology, Pauls Stradins Clinical University Hospital, Riga, Latvia
| | - Yu Pei Eugenia Chock
- Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, Yale University, New Haven, CT, USA
| | - Richard Conway
- Department of Rheumatology, St James's Hospital, Dublin, Ireland
| | - Ali Duarte-García
- Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
| | - Aman Dev Singh
- Department of Community Medicine, GMC Patiala, Punjab, India
| | - Eimear Duff
- Department of Rheumatology, St James's Hospital, Dublin, Ireland
| | | | - Tamer A Gheita
- Rheumatology and Clinical Immunology, Faculty of Medicine, Cairo University, Egypt
| | - Catherine L Hill
- Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, SA, Australia
- Discipline of Medicine, University of Adelaide, Adelaide, SA, Australia
| | | | - Bimba F Hoyer
- Department of Rheumatology and Clinical Immunology, Clinic for Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Evelyn Hsieh
- Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, Yale University, New Haven, CT, USA
- Section of Rheumatology, VA Connecticut Healthcare System, West Haven, CT, USA
| | | | | | - Alfred H J Kim
- Division of Rheumatology, Department of Medicine, Washington University School of Medicine, University of Washington, St Louis, MO, USA
| | - David F L Liew
- Department of Rheumatology, Austin Health, Melbourne, VIC, Australia
- Department of Medicine, University of Melbourne, Melbourne, VIC, Australia
| | - Chieh Lo
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan
| | - Elsa F Mateus
- Portuguese League Against Rheumatic Diseases, Comprehensive Health Research Centre, Lisbon, Portugal
| | - Bruce Miller
- Department of Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Serena Mingolla
- Associazione Nazionale Persone con Malattie Reumatologiche e Rare APMARR APS, Lecca, Italy
| | | | - Jasvinder A Singh
- Medicine Service, VA Medical Center, Birmingham, AL, USA
- Department of Medicine at the School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Namrata Singh
- Division of Rheumatology, Department of Medicine, Washington University School of Medicine, University of Washington, St Louis, MO, USA
| | - Manuel F Ugarte-Gil
- Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud and School of Medicine, Universidad Cientifica del Sur, Lima, Peru
| | | | - Kristen J Young
- Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | | | | | - Wendy Costello
- Irish Children's Arthritis Network (iCAN), Tipperary, Ireland
| | - Rebecca Grainger
- Department of Medicine, University of Otago, Wellington, New Zealand
| | - Pedro M Machado
- Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK
- National Institute for Health Research, University College London Hospitals Biomedical Research Centre, University College London Hospitals National Health Service Foundation Trust, London, UK
- Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK
| | - Philip C Robinson
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
| | | | - Zachary S Wallace
- Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Jinoos Yazdany
- Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | | | - Maggie J Larché
- Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada
- Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Mitchell Levine
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- Department of Clinical Pharmacology & Toxicology, McMaster University, Hamilton, ON, Canada
| | - Gary Foster
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Lehana Thabane
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada
| | - Jonathan S Hausmann
- Program in Rheumatology, Boston Children's Hospital and Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Jeffrey A Sparks
- Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Julia F Simard
- Department of Epidemiology and Population Health, and Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA
| |
Collapse
|
12
|
Tavares ACFMG, de Melo AKG, Cruz VA, de Souza VA, de Carvalho JS, Machado KLLL, de Azevedo Valadares LD, Dos Reis Neto ET, de Rezende RPV, de Resende Guimarães MFB, Ferreira GA, de Sousa Braz A, de Abreu Vieira RMR, de Medeiros Pinheiro M, Ribeiro SLE, Bica BEGR, Baptista KL, da Costa IP, Marques CDL, Lopes MLL, Martinez JE, Giorgi RDN, da Mota LMH, da Rocha Loures MAA, Dos Santos Paiva E, Monticielo OA, Xavier RM, Kakehasi AM, Pileggi GCS. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force. Adv Rheumatol 2022; 62:3. [PMID: 35039077 PMCID: PMC8762982 DOI: 10.1186/s42358-022-00234-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 01/08/2022] [Indexed: 12/26/2022] Open
Abstract
Objective To provide guidelines on the coronavirus disease 2019 (COVID-19) vaccination in patients with immune-mediated rheumatic diseases (IMRD) to rheumatologists considering specific scenarios of the daily practice based on the shared-making decision (SMD) process.
Methods A task force was constituted by 24 rheumatologists (panel members), with clinical and research expertise in immunizations and infectious diseases in immunocompromised patients, endorsed by the Brazilian Society of Rheumatology (BSR), to develop guidelines for COVID-19 vaccination in patients with IMRD. A consensus was built through the Delphi method and involved four rounds of anonymous voting, where five options were used to determine the level of agreement (LOA), based on the Likert Scale: (1) strongly disagree; (2) disagree, (3) neither agree nor disagree (neutral); (4) agree; and (5) strongly agree. Nineteen questions were addressed and discussed via teleconference to formulate the answers. In order to identify the relevant data on COVID-19 vaccines, a search with standardized descriptors and synonyms was performed on September 10th, 2021, of the MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and LILACS to identify studies of interest. We used the Newcastle–Ottawa Scale to assess the quality of nonrandomized studies. Results All the nineteen questions-answers (Q&A) were approved by the BSR Task Force with more than 80% of panelists voting options 4—agree—and 5—strongly agree—, and a consensus was reached. These Guidelines were focused in SMD on the most appropriate timing for IMRD patients to get vaccinated to reach the adequate covid-19 vaccination response. Conclusion These guidelines were developed by a BSR Task Force with a high LOA among panelists, based on the literature review of published studies and expert opinion for COVID-19 vaccination in IMRD patients. Noteworthy, in the pandemic period, up to the time of the review and the consensus process for this document, high-quality evidence was scarce. Thus, it is not a substitute for clinical judgment. Supplementary Information The online version contains supplementary material available at 10.1186/s42358-022-00234-7.
Collapse
Affiliation(s)
| | - Ana Karla Guedes de Melo
- Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, R. Tab. Stanislau Eloy, 585 - Castelo Branco, João Pessoa, Paraíba, 58050-585, Brazil.
| | - Vítor Alves Cruz
- Hospital das Clínicas, Universidade Federal de Goiás, Goiânia, Brazil
| | | | | | | | | | | | | | | | | | - Alessandra de Sousa Braz
- Hospital Universitário Lauro Wanderley, Universidade Federal da Paraíba, R. Tab. Stanislau Eloy, 585 - Castelo Branco, João Pessoa, Paraíba, 58050-585, Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Widdifield J, Eder L, Chen S, Kwong JC, Hitchon C, Lacaille D, Aviña-Zubieta JA, Svenson LW, Bernatsky S. COVID-19 Vaccination Uptake among individuals with Immune-Mediated Inflammatory Diseases in Ontario, Canada between December 2020 and October 2021: A population-based analysis. J Rheumatol 2022; 49:531-536. [PMID: 35034001 DOI: 10.3899/jrheum.211148] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2021] [Indexed: 12/04/2022]
Abstract
OBJECTIVE We assessed COVID-19 vaccine uptake among individuals with immune-mediated inflammatory diseases (IMID) and the Ontario general population. METHODS We studied all residents 16 years and older who were alive and enrolled in Ontario's universal health insurance plan as of December 14, 2020 when vaccination commenced (n=12,435,914). Individuals with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (PsO), and inflammatory bowel disease (IBD) were identified using established disease-specific case definitions applied to health administrative data. Vaccination status was extracted from the provincial COVaxON registry. Weekly cumulative proportions of first and second doses up until October 3, 2021 were expressed as the vaccinated percentage of each disease group, and compared to the general Ontario population, and stratified by age. RESULTS By October 3, 2021, the cumulative percentage with at least one dose was 82.1% for the general population, 88.9% for RA, 87.4% for AS, 90.6% for PsA, 87.3% for PsO, and 87.0% for IBD. There was also a higher total cumulative percentage with two doses among IMIDs (83.8-88.2%) vs the general population (78.0%). The difference was also evident when stratifying by age. Individuals with IMIDs in the youngest age group initially had earlier uptake than the general population but remain the lowest age group with two doses (70.6% in the general population vs. 73.7-79.2% across IMID groups). CONCLUSION While implementation of COVID-19 vaccination programs has differed globally, these Canadian estimates are the first to reassuringly show higher COVID-19 vaccine uptake among individuals with IMIDs.
Collapse
Affiliation(s)
- Jessica Widdifield
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| | - Lihi Eder
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| | - Simon Chen
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| | - Jeffrey C Kwong
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| | - Carol Hitchon
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| | - Diane Lacaille
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| | - J Antonio Aviña-Zubieta
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| | - Lawrence W Svenson
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| | - Sasha Bernatsky
- Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto; University of Toronto, and Women's College Research Institute, Women's College Hospital ICES; Department of Family and Community Medicine, Faculty of Medicine, University of Toronto; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario, Toronto, Canada; Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; Division of Rheumatology, Department of Medicine, University of British Columbia, Arthritis Research Canada; Arthritis Research Canada, and Division of Rheumatology, Department of Medicine, University of British Columbia; Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Canada, Division of Preventive Medicine, University of Alberta, Edmonton, Canada, School of Public Health, University of Alberta, Edmonton, Canada, Department of Community Health Sciences, University of Calgary, Calgary, Canada; Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec. Corresponding Author: Jessica Widdifield Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto ON, M4N 3M5 E-mail:
| |
Collapse
|
14
|
Hidayana I, Amir S, Pelupessy DC, Rahvenia Z. Using a health belief model to assess COVID-19 vaccine intention and hesitancy in Jakarta, Indonesia. PLOS GLOBAL PUBLIC HEALTH 2022; 2:e0000934. [PMID: 36962574 PMCID: PMC10021901 DOI: 10.1371/journal.pgph.0000934] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Accepted: 09/10/2022] [Indexed: 01/31/2023]
Abstract
Since January 2021, Indonesia has administered a nationwide COVID-19 vaccination. This study examined vaccine intention and identified reasons for vaccine hesitancy in the capital city of Jakarta. This is a cross-sectional online survey using the Health Belief Model (HBM) to assess vaccine intent predictors and describe reasons for hesitancy among Jakarta residents. Among 11,611 respondents, 92.99% (10.797) would like to get vaccinated. This study indicated that all HBM constructs predict vaccine intention (P< 0.05). Those with a high score of perceived susceptibility to the COVID-19 vaccine were significantly predicted vaccine hesitancy (OR = 0.18, 95% CI: 0.16-0.21). Perceived higher benefits of COVID-19 vaccine (OR = 2.91, 95% CI: 2.57-3.28), perceived severity of COVID-19 disease (OR: 1.41, 95% CI: 1.24-1.60), and perceived susceptibility of the current pandemic (OR = 1.21, 95% CI: 1.06-1.38) were significantly predicted vaccination intend. Needle fears, halal concerns, vaccine side effects, and the perception that vaccines could not protect against COVID-19 disease emerged as reasons why a small portion of the respondents (n = 814, 7.23%) are hesitant to get vaccinated. This study demonstrated a high COVID-19 vaccine intention and highlighted the reasons for vaccine refusal, including needle fears, susceptibility to vaccine efficacy, halal issues, and concern about vaccine side effects. The current findings on COVID-19 vaccination show that the government and policymakers should take all necessary steps to remove vaccine hesitancy by increasing awareness of vaccine efficacy and benefit interventions.
Collapse
Affiliation(s)
- Irma Hidayana
- Department Asian Studies/Public Health, St. Lawrence University, Canton, New York, United States of America
- LaporCovid19.org- Bona Indah Plaza A2-B11, Lebak Bulus, Jakarta, Indonesia
| | - Sulfikar Amir
- Sociology Programme, School of Social Sciences, Nanyang Technological University, Singapore, Singapore
| | - Dicky C Pelupessy
- Faculty of Psychology Universitas Indonesia, Kampus UI Depok, Jawa Barat, Indonesia
| | - Zahira Rahvenia
- LaporCovid19.org- Bona Indah Plaza A2-B11, Lebak Bulus, Jakarta, Indonesia
| |
Collapse
|
15
|
Shehab M, Zurba Y, Al Abdulsalam A, Alfadhli A, Elouali S. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study. Vaccines (Basel) 2021; 10:55. [PMID: 35062716 PMCID: PMC8777753 DOI: 10.3390/vaccines10010055] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 12/26/2021] [Accepted: 12/28/2021] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND COVID-19 vaccinations have been shown to be effective in reducing risk of severe infection, hospitalization, and death. They have also been shown to be safe and effective in patients with inflammatory bowel disease (IBD) who are receiving biologic therapies. In this study, we aimed to evaluate the prevalence of vaccination among patients receiving biologic therapies for IBD. METHODS A single-center prospective cross-sectional study conducted at a tertiary care inflammatory bowel disease center in Kuwait. Data from patients with inflammatory bowel disease (IBD) who attended the gastroenterology infusion clinic from 1 June 2021 until 31 October 2021 were retrieved. Patients who received infliximab or vedolizumab at least six weeks before recruitment were included. The primary outcome was prevalence of COVID-19 vaccination. The secondary outcome was to assess whether prevalence of COVID-19 vaccination differed based on sex, age, type of biologic therapy and nationality. RESULTS The total number of inflammatory bowel disease (IBD) patients enrolled in the study was 280 (56.0% male and 44.0% female). Of the total, 112 (40.0%) patients were diagnosed with ulcerative colitis and 168 (60.0%) with Crohn's disease. The number of ulcerative colitis patients who were vaccinated was 49 (43.8%) and the number of Crohn's disease patients who were vaccinated was 68 (40.5%). The median age was 33.2 years and BMI was 24.8 kg/m2. With respect to the total number of patients, 117 (41.8%) were vaccinated with either BNT162b2 or ChAdOx1 nCoV-19 and 163 (58.2%) were not vaccinated. Female patients were more likely to receive the vaccine compared to male patients (83.0% vs. 63.8%, p < 0.001). In addition, patients above the age 50 were more likely to receive the vaccine than patients below the age of 50 (95.6% vs. 31.2% p < 0.001). Expatriates were more likely to receive the vaccine than citizens (84.8% vs. 25.0%, p < 0.001). There was no statistical difference between patients on infliximab and vedolizumab with regard to prevalence of vaccination (40.0% vs 48.0%, p = 0.34). CONCLUSION The overall prevalence of COVID-19 vaccination among patients with inflammatory bowel disease (IBD) on biologic therapies was lower than that of the general population and world health organization (WHO) recom-mendation. Female patients, patients above the age of 50, and expatriates were more likely to receive the vaccine. Physicians should reinforce the safety and efficacy of COVID-19 vaccines among patients, especially IBD patients on biologic therapies, who express hesitancy towards them.
Collapse
Affiliation(s)
- Mohammad Shehab
- Department of Internal Medicine, Mubarak Al-Kabeer University Hospital, Aljabreyah 46300, Kuwait; (Y.Z.); (A.A.A.); (A.A.)
| | - Yasmin Zurba
- Department of Internal Medicine, Mubarak Al-Kabeer University Hospital, Aljabreyah 46300, Kuwait; (Y.Z.); (A.A.A.); (A.A.)
| | - Ali Al Abdulsalam
- Department of Internal Medicine, Mubarak Al-Kabeer University Hospital, Aljabreyah 46300, Kuwait; (Y.Z.); (A.A.A.); (A.A.)
| | - Ahmad Alfadhli
- Department of Internal Medicine, Mubarak Al-Kabeer University Hospital, Aljabreyah 46300, Kuwait; (Y.Z.); (A.A.A.); (A.A.)
| | - Sara Elouali
- Department of Internal Medicine, Cleveland Clinic, Abu Dhabi P.O. Box 112412, United Arab Emirates;
| |
Collapse
|